Share This Page
Suppliers and packagers for generic pharmaceutical drug: mycophenolate mofetil
✉ Email this page to a colleague
mycophenolate mofetil
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Roche Palo | CELLCEPT | mycophenolate mofetil | CAPSULE;ORAL | 050722 | NDA | Genentech, Inc. | 0004-0259-01 | 1 BOTTLE, PLASTIC in 1 CARTON (0004-0259-01) / 100 CAPSULE in 1 BOTTLE, PLASTIC | 1995-05-03 |
| Roche Palo | CELLCEPT | mycophenolate mofetil | CAPSULE;ORAL | 050722 | NDA | Genentech, Inc. | 0004-0259-43 | 1 BOTTLE, PLASTIC in 1 CARTON (0004-0259-43) / 500 CAPSULE in 1 BOTTLE, PLASTIC | 1995-05-03 |
| Accord Hlthcare | MYCOPHENOLATE MOFETIL | mycophenolate mofetil | CAPSULE;ORAL | 090253 | ANDA | Accord Healthcare Inc. | 16729-094-01 | 100 CAPSULE in 1 BOTTLE (16729-094-01) | 2009-05-04 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Mycophenolate Mofetil
Introduction
Mycophenolate mofetil (MMF) is an immunosuppressive agent primarily used to prevent organ rejection in transplant recipients and treat certain autoimmune diseases. As a critical medication in transplant medicine, its supply chain reliability, manufacturing quality, and regulatory compliance are vital for healthcare providers and patients. This report examines key suppliers of mycophenolate mofetil, analyzing their manufacturing capabilities, regulatory standings, and strategic significance within the pharmaceutical market.
Overview of Mycophenolate Mofetil
Mycophenolate mofetil is a prodrug of mycophenolic acid, inhibiting inosine monophosphate dehydrogenase—a key enzyme in guanine nucleotide synthesis—thereby suppressing lymphocyte proliferation. It garnered widespread approval following its introduction in the 1990s and is marketed under various brand names, including CellCept by Roche, Myfortic by Novartis, and generic versions by multiple manufacturers globally.
The complexity of MMF synthesis, combined with stringent regulatory requirements and patent expirations, has resulted in a diverse supplier landscape, comprising both originator companies and generics manufacturers.
Key Suppliers in the Mycophenolate Mofetil Market
1. Roche (Genentech Inc.)
- Product: CellCept (brand-name mycophenolate mofetil)
- Market Role: Originator/Innovator
- Manufacturing Reach: Global facilities in the United States, Europe, and Asia
- Regulatory Status: Fully compliant with FDA, EMA, and other regulatory agencies
- Strategic Significance: As the patent holder until the expiration of key patents (around 2012–2013), Roche has played a dominant role in setting quality standards and supply stability for MMF. Their established global footprint facilitates broad distribution.
2. Novartis (Myfortic)
- Product: Myfortic (enteric-coated mycophenolate sodium, alternative to MMF)
- Market Role: Major player with an alternative formulation
- Manufacturing: Facilities aligned with regulatory standards globally
- Regulatory Status: Approved in major markets, with a focus on alternative delivery mechanisms
- Strategic Context: While not a direct supplier of MMF, Novartis’s presence in the immunosuppressive market influences supply dynamics through complementary formulations.
3. Dr. Reddy's Laboratories
- Product: Generic mycophenolate mofetil
- Market Role: Leading Indian generic manufacturer
- Manufacturing Capabilities: Multiple facilities complying with WHO-GMP standards
- Regulatory Status: Approved by USFDA, EMA, and other agencies, supplying to both domestic and export markets
- Market Significance: Dr. Reddy’s is among the top generic suppliers, with significant global reach, particularly in price-sensitive markets.
4. Mylan (Now part of Viatris)
- Product: Generic mycophenolate mofetil
- Market Role: Major global generic supplier
- Manufacturing: Facilities in India, Europe, and the United States
- Regulatory Status: USFDA, EMA, and other approvals facilitate extensive distribution
- Market Significance: Its broad portfolio and manufacturing capacity secure a consistent supply in numerous regions.
5. Sandoz (Novartis division)
- Product: Generic versions of MMF
- Market Role: Key low-cost supplier
- Manufacturing: Multiple global sites, quality assurance aligned with global standards
- Regulatory Status: Approved by key authorities, supporting supply across geographies
- Strategic Position: Contributes significantly to affordable access, especially in emerging markets.
6. Synthon
- Product: Generic mycophenolate mofetil
- Market Role: European-focused supplier
- Manufacturing Capabilities: Facilities in Europe adhering to EU-GMP
- Regulatory Status: Approved in multiple European countries
- Strategic Significance: As a smaller but reliable supplier, Synthon enhances market competition.
7. Sun Pharmaceutical Industries
- Product: Generic mycophenolate mofetil
- Market Role: Leading Indian manufacturer
- Manufacturing: Facilities compliant with WHO-GMP and USFDA standards
- Regulatory Status: Approved across various jurisdictions
- Market Importance: Enabling affordable supply, especially in developing countries.
8. Cipla
- Product: Mycophenolate mofetil
- Market Role: Noted for cost-effective generics
- Manufacturing: Indian facilities certified with international standards
- Regulatory Approvals: USFDA, EDQM, and others
- Market Impact: Critical in expanding access to immunosuppressants in emerging markets.
9. Hetero Drugs
- Product: Generic mycophenolate mofetil
- Market Role: Focused on Indian and Asian markets
- Manufacturing: Certified facilities meeting international standards
- Regulatory Status: Approvals in multiple emerging market countries
- Market Influence: Growing role as a cost-efficient producer.
10. Teva Pharmaceutical Industries
- Product: Generic MMF (though availability varies)
- Market Role: Major generic supplier with a broad portfolio
- Manufacturing: Global facilities with stringent regulatory compliance
- Regulatory Status: Approved in several jurisdictions
- Market Significance: Supports supply stability, especially in North America and Europe.
Supply Chain Considerations
The supply chain of mycophenolate mofetil has become more complex following patent expirations of Roche's CellCept and the ensuing surge in generic manufacturing. Ensuring consistent quality, regulatory compliance, and capacity is essential for healthcare providers who rely on MMF for transplant success.
Global supply is heavily reliant on Indian and Chinese manufacturers, necessitating vigilant regulatory oversight. Supply disruptions are less common but can be triggered by manufacturing issues, raw material shortages, or geopolitical factors. Multiple suppliers across different regions mitigate these risks.
Regulatory and Quality Standards
Suppliers adhere to international Good Manufacturing Practices (GMP) mandated by agencies such as the USFDA, EMA, PMDA, and WHO. These standards ensure drug consistency, safety, and efficacy.
- USFDA approvals are considered a benchmark for quality, influencing procurement choices in North America and other regions.
- EMA approvals facilitate access across Europe and other jurisdictions.
- Several Indian and Chinese suppliers also maintain compliance with these standards to access global markets.
Market Dynamics and Strategic Implications
Manufacturers with established regulatory approvals and scalable manufacturing capacities dominate global supply. Patent expiries have fostered an influx of generic suppliers, increasing competition but also raising concerns over quality consistency. Strategic partnerships, licensing agreements, and ongoing R&D investments support suppliers’ positions.
Pharmaceutical companies evaluating suppliers must balance pricing, regulatory commitments, manufacturing reliability, and geographical considerations. Diversified supplier portfolios are crucial for ensuring uninterrupted supply, especially during global crises like the COVID-19 pandemic.
Conclusion
The supply ecosystem for mycophenolate mofetil is characterized by a mixture of originator companies and a proliferation of reputable generic manufacturers. Key players such as Roche, Dr. Reddy’s, Mylan/Viatris, and Sandoz dominate due to their regulatory compliance and manufacturing capacities. Emerging manufacturers from Asia, notably India and China, significantly contribute through cost-effective production aligned with international quality standards.
Stakeholders must prioritize supplier diversity, rigorous quality assurance, and ongoing regulatory engagement to mitigate risks and ensure reliable access to this essential immunosuppressive medication.
Key Takeaways
- Dominant Suppliers: Roche (originator), Dr. Reddy’s, Mylan/Viatris, Sandoz, Sun Pharma.
- Growing Generic Market: Post-patent expiration has expanded global supply, particularly from Indian and Chinese manufacturers.
- Regulatory Compliance: USFDA and EMA approvals are critical benchmarks; suppliers adhering to these standards have a competitive edge.
- Supply Risks: Disruptions could arise from manufacturing issues or geopolitical challenges; diversification mitigates risks.
- Market Trends: Price competition and regulatory harmonization continue to shape the supply landscape.
Frequently Asked Questions
1. Who are the main global suppliers of mycophenolate mofetil?
The leading suppliers include Roche (as the originator), along with major generic manufacturers like Dr. Reddy’s Laboratories, Mylan/Viatris, Sandoz, Sun Pharma, and Synthon.
2. How has patent expiration impacted the mycophenolate mofetil market?
Patent expirations spurred the entry of multiple generic manufacturers, increasing market competition, reducing prices, and expanding global access, especially in developing regions.
3. What quality standards do suppliers of MMF adhere to?
Suppliers comply with international GMP guidelines set by agencies like USFDA, EMA, and WHO, ensuring drug safety, quality, and efficacy.
4. Are there supply concerns regarding mycophenolate mofetil?
While generally stable, potential disruptions may stem from manufacturing issues, raw material shortages, or geopolitical factors—hence the importance of supply chain diversification.
5. Why is supplier diversification important in the MMF market?
Diversification reduces dependency on single sources, mitigates supply risks, and promotes competitive pricing, ultimately ensuring continuity of access for patients.
Sources:
[1] "Mycophenolate Mofetil Manufacturing and Market Analysis," GlobalData, 2022.
[2] FDA Drug Approvals Database, U.S. Food and Drug Administration.
[3] "European Medicines Agency - Mycophenolate Mofetil," EMA, 2023.
[4] Company websites and regulatory filings of Roche, Dr. Reddy’s, Mylan, Sandoz, Sun Pharma, Synthon, Cipla, and Hetero.
More… ↓
